Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas Looks to Fortify China Biz via Global Commercial Rejig
April 26, 2019
- Astellas’ Net Profit Soars 35% on Xtandi, Betanis
April 26, 2019
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
- Daiichi Sankyo to Move Up Japan Filing of DS-8201 to FY2019 H2
April 26, 2019
- CSL Behring Seeks Additional Indication for Privigen
April 26, 2019
- Ninlaro Filed in Japan for Post-Transplant Maintenance: Takeda
April 26, 2019
- Takeda Files Japan NDA for Cabozantinib, Exelixis’ RCC Treatment
April 26, 2019
- Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
- Takeda Cuts FY2018 Profit Outlook on Shire Takeover
April 26, 2019
- Delgocitinib Shows Good PIII Results in Pediatric Atopic Dermatitis: JT, Torii
April 26, 2019
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
- Daiichi Sells Nihonbashi Building to Raise Funds for Oncology R&D
April 26, 2019
- Fujifilm Toyama Chemical Files Solithromycin for ENT Infection Diseases
April 26, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Boehringer’s Japan Ethical Drug Sales in 2018 Sink 18.4% on Micardis Cliff
April 25, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Chugai to Erect New Manufacturing Building for Small, Middle Molecule APIs
April 25, 2019
- Over 170 Staffers to Quit Chugai at June-End: Voluntary Redundancy
April 25, 2019
- Kyowa Kirin Seeks Additional Indication for Orkedia
April 25, 2019
- Poxel’s Novel Diabetes Med One Step Closer to World’s 1st Launch, Japan Chief Says Physicians’ Trust Holds Key
April 24, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…